gestedNACTinlieuofprimarydebulkingisassociatedwith aninferioroverallsurvival [11] .Thus,thereisstillnocompellingevidencethatNACTpriortodebulkingsurgeryisasuperiorstrategyatthepresenttime [12] .
Amongtheir60patientstreatedbyNACTandintervalde-bulking,Limetal. [7] reported100%successinachievingless than1cmofresidualdiseaseand35%ofthesepatientshad complete cytoreduction to no visible tumor. In the unpublished phase III European trial of primary debulking versus NACT plus interval debulking that is referenced in abstract form [13] , optimal debulking was identified as the strongest independentprognosticfactor,butthetimingofsurgerydid notseemtomatter.ItwouldseemthatadditionalradicalproceduresmightbeindicatedinthepopulationofLimetal.to increasethepercentageofcompleteresection,butitisdifficulttounderstandhowremovalofregressedtumorsishelpful whenmiliaryorsmallvolumediseaseisleftbehindinother areas. The manuscript does not provide details about which patientshadwhatprocedureperformed.
The authors' hypothesis is provocative, but their data do notsubstantiatetheclaimthatclinicallyimportantnon-palpableregressedtumorwarrantsradicaldissectionatthetimeof intervaldebulking.ItisinterestingtospeculatethatCSCmay reside in these tissues and removal would facilitate eradicationoftheresidual,morechemoresistanttumorcells.Based on their reported observations, this possibility remains just that -speculation. Nevertheless, many of the characteristics ofovariancancerindirectlyargueinfavorofeitherthisdiseasebeingaproductofCSCorCSCpotentiallycontributing to the pathogenesis and/or recurrence of the disease. Moreover, subsets of ovarian tumor cells have been identified, functionallycharacterized,andshowntohavetumorinitiating capacityandsharemanyofthecharacteristicsnormallyattribJoeV.Meigs,asurgeonatMassachusettsGeneralHospital, initiallydescribedthetechniqueofovariantumordebulking in1934 [1] .Theconceptdidnotreallycatchonuntilthemid1970swhenC.ThomasGriffithspublishedapapersuggesting asurvivalbenefit [2] .Numerouscaseseriesandotherretrospective reports rapidly followed and further supported the efficacyofthisaggressivesurgicalapproach [3] [4] [5] .Oneofthe theoreticalargumentsthatisoftenmadeinfavorofdebulking isthatremovalofchemo-resistantclones-orovariancancer stemcells(CSC)-isadvantageous [6] .
InthisissueofOnkOlOgie,Limetal. [7] postulatethatresidual cancer stem cells reside within regressed tumors after partial treatment with neoadjuvant chemotherapy (NACT). They advocate radical procedures during interval debulking surgerytoremovetheseclonesandconcludethatthisstrategy resultsinaclinicalbenefit(mediansurvival55months)when comparedtohistoricalcontrols.Themanuscripthasallofthe limitationsofaretrospectivereview,inadditiontothebiasof patientselection.Unfortunately,thereisnomentionofmorbidity,timeofdischargeorothercomplicationsthatmayhave either directly or indirectly resulted from aggressive surgery toremovesubclinicaldisease.
As the authors mention, cytoreductive status is the most importantprognosticfactorinpatientswithadvancedovarian cancerundergoingsurgery.Inprimarydebulkingsurgery,survivalrateshavebeenshowntoimproveaccordinglywhenthe paradigm is revised to a more aggressive philosophy incorporating ultra-radical techniques such as splenectomy, diaphragmaticstrippingandliverresection [8] .NACTfollowed by interval debulking often results in fewer radical procedures,higherratesofoptimaldebulking,lessmorbidityandin some series comparable survival compared to primary debulking surgery [9, 10] . However, other reports have sugOnkologie2010;33:286-287
OvarianCancer:SurgicalDebulkingBeforeor AfterChemotherapy 287 utedtobenignstemcells [14] [15] [16] [17] .Theauthorsappreciatethe ideathatCSCaremorelikelytobechemoresistantandthisis believedtobedueinparttoanincreaseinmultidrugtransporter activity and their relative quiescence which renders them less susceptible to current chemotherapy protocols whichtargetreplicatingcells.
Itisgenerallybelievedthatthenumberoftumorcellsthat have the capacity to initiate new tumor is relatively small. Whether these CSC are distributed throughout the tumor or limitedtofocalareasintheprimaryormetastaticlesion(s)is yettobedetermined.Theideathatmoreaggressivesurgical procedures immediately prior to chemotherapy or following NACT will serve to eliminate CSC and/or progenitor cells is aninterestingargument.However,giventhatoptimaldebulkingisdefinedasleavingnoresidualtumorgreaterthan1cmin masswouldsuggestthatunlesschemotherapyismoreeffective inlessbulkydiseasethechancesthatoneprocedurewouldbe more effective over the other in eliminating the presumed CSC population is not readily obvious. Residual stem cells have been shown in other tumor types following chemotherapy or radiation [18] [19] [20] [21] . More interesting, however, it has beenreportedthatCSCremainorinsomeinstancesincrease innumberafterchemotherapyorradiation [18] [19] [20] [21] .Whether thereistrulyanoverallincreaseorjustachangeintheratioof stem-progenitor to more differentiated cells is not always clear.Thestabilityofthestemcellnichemustalsobeconsidered.Ifchemotherapyistargetingthemorerapidlyproliferating tumor cells and/or the vascular component thereby disruptingthebulkofthetumormicroenvironment,thesurviving cancer stem-progenitor cells would need to not only survive the toxicity but also 're-awaken' and undergo some form of asymmetricorsymmetricreplicationprocesstosecureandrecruitaviablebloodsupplyalongwithsupportivesomaticcells.
Whiletherearelimitationstothisstudytheauthors'hypothesis is intriguing and potentially testable. We agree there is a need for more extensive and well designed prospective studies investigating the role of CSC in recurrent disease andhowtheymayinfluencesurgicalmanagementofovarian cancer.
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